Abstract
TP53 (which encodes p53) is one of the most frequently mutated genes in cancers. In this study, we generated TP53-mutant pigs by gene editing via electroporation of the Cas9 protein (GEEP), a process that involves introducing the Cas9 protein and single-guide RNA (sgRNA) targeting exon 3 and intron 4 of TP53 into in vitro-fertilized zygotes. Zygotes modified by the sgRNAs were transferred to recipients, two of which gave birth to a total of 11 piglets. Of those 11 piglets, 9 survived. Molecular genetic analysis confirmed that 6 of 9 live piglets carried mutations in TP53, including 2 piglets with no wild-type (WT) sequences and 4 genetically mosaic piglets with WT sequences. One mosaic piglet had 142 and 151 bp deletions caused by a combination of the two sgRNAs. These piglets were continually monitored for 16 months and three of the genome-edited pigs (50%) exhibited various tumor phenotypes that we presumed were caused by TP53 mutations. Two mutant pigs with no WT sequences developed mandibular osteosarcoma and nephroblastoma. The mosaic pig with a deletion between targeting sites of two sgRNAs exhibited malignant fibrous histiocytoma. Tumor phenotypes of TP53 mosaic mutant pigs have not been previously reported. Our results indicated that the mutations caused by gene editing successfully induced tumor phenotypes in both TP53 mosaic- and bi-allelic mutant pigs.
Highlights
People are living longer than ever; the number of cancer patients is expected to increase as a result of the high incidence of cancer later in life
We introduced the Cas9 protein with single-guide RNA (sgRNA) into in vitro-fertilized zygotes by electroporation
We confirmed that two types of sgRNAs, sgRNA1 and sgRNA2, targeted TP53 exon 3 and intron 4, respectively (S1 Fig), leading to highly efficient gene editing
Summary
People are living longer than ever; the number of cancer patients is expected to increase as a result of the high incidence of cancer later in life. Despite the importance of small rodents, such as mice and rats, for preclinical drug studies, these taxa are limited by their considerable differences from humans (e.g., differences in body size, general physiology, anatomy, and lifespan). Alternative genetically defined cancer models are needed, including. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.